The invention concerns a novel peptide with the amino acid sequence Thr-Ser-Arg-Gly-Asp-His-Glu-Leu-Leu-NH₂ (TSRGDHELL-amide), derived from the fibrinogen-like domain of the human angiopoietin-like protein (ANGPTL6).
The peptide acts as a potent stimulator of chondrogenesis, promoting the differentiation of adipose-derived mesenchymal stem cells (ASCs) into chondrocytes.
It also enhances proliferation, migration, and chemotaxis of stem cells, making it a promising tool for cartilage repair.In vitro studies have demonstrated that AGF9 independently induces ASC differentiation into chondrocytes, while in vivo models confirmed its regenerative effect on damaged cartilage.
Due to its low toxicity and immunological safety, the peptide can be applied intra-articularly as a novel biological regenerative drug.
Application:
- Biological drug supporting cartilage regeneration,
- Chondrogenesis stimulator in cell-based therapies,
- Differentiation factor inducing stem cells into chondrocytes.
